Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)
- Etrasimod CR profile designed to retain etrasimod's rapid onset of action while further improving its potentially best-in-class, non-titrated, low intrinsic first-dose heart rate effect - Positive topline data from Phase 1 study demonstrated significant reduction in heart rate effect,
View HTML
Toggle Summary Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor
SAN DIEGO , March 30, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that James C. Mullen has agreed to serve as an independent senior advisor to the Company. "We are honored to have Jim as an advisor to Arena. In a rapidly evolving industry, and especially in
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , March 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on March 12, 2020 , the Compensation Committee of its Board of Directors approved inducement stock options and inducement performance restricted stock units ("PRSUs") to new employees that
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 21, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new employees. 
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Upcoming Investor Conferences
SAN DIEGO , Feb. 20, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , President and Chief Executive Officer, will present at the upcoming investor conferences: SVB Leerink 9th Annual Global Healthcare Conference – Presenting on Tuesday, February
View HTML
Toggle Summary Arena Pharmaceuticals' Presence at the European Crohn's and Colitis Organisation (ECCO) Congress Further Highlights Commitment to the GI Community
- New biomarker data from the open-label extension (OLE) of the Phase 2 OASIS trial for etrasimod in patients with moderately to severely active ulcerative colitis (UC) - Arena sponsored dinner symposium: HYPE, HOPE or REALITY? Integrating histology into a treat-to-target strategy in UC, with
View HTML
Toggle Summary FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients
- APD418 currently in Phase 1 clinical investigation - data expected this year SAN DIEGO , Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration ( FDA ) granted Fast Track designation for APD418, a β 3 -adrenergic
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary
SAN DIEGO , Jan. 13, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Joan Schmidt as Executive Vice President, General Counsel and Secretary. Ms. Schmidt will join Arena formally in March 2020 and report to Amit D.
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16
SAN DIEGO , Jan. 8, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 38 th Annual J.P. Morgan Healthcare Conference on Thursday, January 16 , at 1:00 PM
View HTML
Toggle Summary Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years
- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD) - Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata (AA) - First subject dosed in APD418 Ph 1 trial in Decompensated Heart Failure (DHF) - Expanded multi-program collaboration
View HTML